Next Article in Journal
Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?
Previous Article in Journal
Possible Metastatic Stage-Dependent ILC2 Activation Induces Differential Functions of MDSCs through IL-13/IL-13Rα1 Signaling during the Progression of Breast Cancer Lung Metastasis
Previous Article in Special Issue
Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 13
10.3390/cancers14133268
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cancers 2021, 13(15), 3830.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830

by
Ken Kudura
1,*,
Florentia Dimitriou
2,
Lucas Basler
3,
Robert Förster
4,
Daniela Mihic-Probst
5,
Tim Kutzker
6,
Reinhard Dummer
2,
Joanna Mangana
2,
Irene A. Burger
1,7 and
Michael C. Kreissl
8
1
Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
2
Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland
3
Center for Proton Therapy, Paul Scherrer Institute, 5232 Villigen, Switzerland
4
Institute of Radiation Oncology, Cantonal Hospital Winterthur, 8400 Winterthur, Switzerland
5
Institute of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland
6
Faculty of Applied Statistics, Humboldt University Berlin, 10117 Berlin, Germany
7
Department of Nuclear Medicine, Cantonal Hospital Baden, 5404 Baden, Switzerland
8
Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, University Hospital Magdeburg, 39120 Magdeburg, Germany
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(13), 3268; https://doi.org/10.3390/cancers14133268
Submission received: 30 June 2021 / Accepted: 26 July 2021 / Published: 4 July 2022
(This article belongs to the Special Issue Biomarkers of Immune Checkpoint Therapy Response and Resistance)
Versions Notes
The authors wish to make the following corrections to this paper [1]:
  • Add a citation in the Introduction section
In the original publication, the publication from Lucas Basler et al. [2] was not cited. The citation has now been inserted in the Introduction as reference [9]:
In order to predict the response to immunotherapy several outcome predictive biomarkers based on the histopathology of the primary tumor (i.e., tumor thickness, ulceration, mitotic rate) [8], standard blood samples (i.e., lactate dehydrogenase LDH, calcium-binding protein B S100B) [9] or clinical aspects (i.e., sentinel lymph node involvement, anatomical site of primary tumor, gender or age) [10] have been already discussed in the literature.”
2.
Ethical approval information needs to be updated:
The official and correct reference of the stated ethical approval is KEK-ZH-Nr: 2014-0193.
The correct statement is as below:
Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Cantonal Ethics Committee of the Canton Zurich in Switzerland (protocol code KEK-ZH-Nr: 2014-0193) on 15 March 2017.
2.1. Patient Cohort
(…). All included patients consented the use of their clinical data for research purposes. This study was approved by the local ethics committee (protocol code KEK-ZH-Nr: 2014-0193) and conducted in compliance with Good Clinical Practice GCP-rules and the Declaration of Helsinki.
3.
Missing Funding
In the original publication, the funder Cancer Research Center, Comprehensive Center Zurich, University Hospital Zurich (CRC_13) was not included.
The correct statement is as:
Funding: This research was funded by the Iten-Kohaut-Foundation (IA USZF27071) and the Cancer Research Center, Comprehensive Center Zurich, University Hospital Zurich (CRC_13).
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.

References

  1. Kudura, K.; Dimitriou, F.; Basler, L.; Förster, R.; Mihic-Probst, D.; Kutzker, T.; Dummer, R.; Mangana, J.; Burger, I.A.; Kreissl, M.C. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830. [Google Scholar] [CrossRef]
  2. Basler, L.; Gabryś, H.S.; Hogan, S.A.; Pavic, M.; Bogowicz, M.; Vuong, D.; Tanadini-Lang, S.; Förster, R.; Kudura, K.; Huellner, M.W.; et al. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma treated with Immune Checkpoint Inhibition. Clin. Cancer Res. 2020, 26, 4414–4425. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kudura, K.; Dimitriou, F.; Basler, L.; Förster, R.; Mihic-Probst, D.; Kutzker, T.; Dummer, R.; Mangana, J.; Burger, I.A.; Kreissl, M.C. Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830. Cancers 2022, 14, 3268. https://doi.org/10.3390/cancers14133268

AMA Style

Kudura K, Dimitriou F, Basler L, Förster R, Mihic-Probst D, Kutzker T, Dummer R, Mangana J, Burger IA, Kreissl MC. Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830. Cancers. 2022; 14(13):3268. https://doi.org/10.3390/cancers14133268

Chicago/Turabian Style

Kudura, Ken, Florentia Dimitriou, Lucas Basler, Robert Förster, Daniela Mihic-Probst, Tim Kutzker, Reinhard Dummer, Joanna Mangana, Irene A. Burger, and Michael C. Kreissl. 2022. "Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830" Cancers 14, no. 13: 3268. https://doi.org/10.3390/cancers14133268

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop